Basic Suprax Information

• INN (International Nonproprietary Name): Cefixime.
• Brand Names Available In Canada (English): Suprax (tablets 400 mg, oral suspension 100 mg/5 mL, chewable tablets, capsules).
• ATC Code: J01DD08 (third‑generation cephalosporin antibiotic, systemic use).
• Forms & Dosages: Tablets 400 mg; capsules 400 mg; chewable tablets 100 mg and 200 mg; oral suspension 100 mg/5 mL and 200 mg/5 mL.
• Manufacturers In Canada (English): Sanis Health Inc and generic suppliers.
• Registration Status In Canada (English): Health Canada authorized with DINs 00868981 (400 mg tablet) and 00868965 (100 mg/5 mL suspension); prescription‑only.
• OTC / Rx Classification: Prescription only (Rx) across observed markets.

Key Findings From Recent Trials

Major 2022–2025 Canadian & Global Studies

Main Outcomes

Surveillance and clinical reports from 2022–2025 show the strongest signals relate to changes in antimicrobial susceptibility and ongoing population‑level safety monitoring.

Provincial reference laboratories, Public Health Agency of Canada summaries, and international trend reports identified localized increases in reduced susceptibility to third‑generation cephalosporins for Neisseria gonorrhoeae in some regions.

Those resistance signals prompted guideline updates that favour dual or alternative therapy for gonorrhea in affected areas rather than empirical cefixime monotherapy.

Randomized and observational studies examined single‑dose cefixime 400 mg for uncomplicated gonorrhea and short 5–10 day courses for respiratory and urinary infections where local resistance is low.

Where local antibiograms show susceptibility, clinical efficacy for standard oral cefixime regimens remains acceptable.

Safety Observations

Post‑market safety monitoring between 2022 and 2025 emphasises Clostridioides difficile risk, especially in older adults and recent broad‑spectrum antibiotic recipients.

Reports continue to highlight the importance of renal monitoring and dose adjustments; product labels and Health Canada monographs recommend a 50% dose reduction for creatinine clearance below 60 mL/min.

Clinical takeaway: use suprax guided by local antibiogram data and avoid empirical cefixime if resistant gonorrhea is suspected.

Patients at higher risk of diarrhoeal complications should be monitored closely while on cefixime therapy.

Clinical Mechanism Of Action

Layman’s Explanation

Cefixime is an oral antibiotic that stops bacteria from building their protective cell wall, causing them to burst and die.

This action makes it useful for common bacterial infections such as urinary tract infections, otitis media, and pharyngitis as described in Health Canada monographs.

Patients often hear it described as a medicine that weakens the bug’s shell so the immune system can clear the infection.

Scientific Breakdown

Beta‑Lactam Binding & Bacterial Kill Kinetics

Cefixime belongs to the third‑generation cephalosporins and binds penicillin‑binding proteins (PBPs) on susceptible bacteria.

Binding blocks transpeptidation during peptidoglycan synthesis and prevents proper cell‑wall formation.

Its oral bioavailability allows once‑daily dosing in many adult regimens, commonly 400 mg once daily, with activity skewed toward Gram‑negative organisms and some Gram‑positives.

Killing is time dependent, so clinical efficacy correlates with the proportion of the dosing interval that plasma concentrations exceed the MIC (time above MIC).

Pharmacokinetics: oral absorption varies, renal excretion predominates, and dose reduction by 50% is advised for creatinine clearance under 60 mL/min.

Resistance mechanisms include extended‑spectrum beta‑lactamases (ESBLs) and PBP alterations, which reduce cefixime activity and should prompt reliance on local antibiograms before use.

Scope Of Approved & Off‑Label Use

Health Canada Approvals (DIN‑Based)

Health Canada‑registered formulations include Suprax tablets (DIN 00868981, 400 mg) and oral suspension (DIN 00868965, 100 mg/5 mL).

Official indications in product monographs align with common international labels: uncomplicated urinary tract infections, otitis media, pharyngitis/tonsillitis, and certain respiratory infections.

Some guidelines reflect single‑dose cefixime 400 mg for uncomplicated gonorrhea when susceptibility is presumed.

Notable Off‑Label Trends In Canadian Practice

Off‑label uses in primary care and paediatric settings include treating suspected bacterial outpatient bronchitis and stepping down from IV third‑generation cephalosporins when the organism is susceptible.

Pediatric dosing is weight based, typically 8 mg/kg once daily, and limited to children older than six months as per the monograph.

Off‑label prescribing should be supported by culture results or local antibiogram evidence, and documentation of informed consent is advised.

Pharmacist counselling should reinforce monitoring and clear follow‑up plans for off‑label courses of therapy.

Dosage Strategy

General Dosing Per Health Canada Monographs

Typical adult dosing is 400 mg once daily or 200 mg twice daily depending on indication.

Pediatric dosing for children six months to 12 years is commonly 8 mg/kg once daily or 4 mg/kg every 12 hours, adjusted to available formulations.

Usual treatment duration is five to ten days for most infections, with single‑dose regimens used in selected gonorrhea cases where advised by guidelines.

Condition‑Specific Dosing Adjustments

For uncomplicated urinary tract infections both 400 mg once daily and 200 mg twice daily regimens are used.

Otitis media and pharyngitis often use 400 mg once daily for five to ten days.

For uncomplicated gonorrhea, a single 400 mg dose has been used where local susceptibility supports its use.

Reduce the dose by 50% if creatinine clearance is under 60 mL/min and review renal function in elderly patients before standard dosing.

If a dose is missed, advise the patient to take it when remembered unless the next dose is near; do not double doses.

Safety Protocols

Contraindications (Canadian Advisories)

Absolute contraindications include known severe hypersensitivity to cefixime, other cephalosporins, or excipients in the formulation.

Exercise caution in patients with a history of severe penicillin allergy because of possible cross‑reactivity.

Use caution in patients with pre‑existing gastrointestinal disease, especially colitis, due to C. difficile risk.

Adverse Effects (Post‑Market Reports)

Common adverse events reported include diarrhoea, abdominal pain, nausea, and rash.

Serious but rare reactions reported in post‑market surveillance include anaphylaxis, Stevens‑Johnson syndrome, cytopenias, and C. difficile colitis.

Elderly patients and those recently treated with broad‑spectrum antibiotics are at higher risk for C. difficile infection.

Management: stop therapy for severe allergic or cutaneous reactions, test for C. difficile when severe diarrhoea occurs, and report serious events to Health Canada.

Monitor renal function and reduce dose per monograph recommendations for CrCl <60 mL/min to limit toxicity.

Interaction Mapping

Food Interactions Common In Canadian Diet

Food moderately affects cefixime absorption, and administration with or without food is permitted.

Clinicians commonly advise patients to take suprax the same way each day to reduce variability, for example always with or without a meal.

Typical Canadian high‑fat meals may slightly reduce peak concentration but generally do not require dose changes.

Drug Combinations Flagged By Health Canada

No major CYP interactions are reported for cefixime, simplifying co‑prescribing with many oral drugs.

Use caution with concomitant nephrotoxic agents and monitor renal function when combined therapy could affect clearance.

Evidence of an interaction with oral contraceptives is limited, but advise backup contraception if diarrhoea occurs during therapy.

Avoid unnecessary concomitant broad‑spectrum antibiotics to reduce C. difficile risk and monitor anticoagulated patients if absorption or diarrhoea alters bleeding risk.

Patient Experience Analysis

Canadian Survey Data

Canadian patient surveys and community‑pharmacy feedback from 2022–2025 report good overall tolerability for oral cefixime.

The most frequent complaints are gastrointestinal, especially loose stools and abdominal discomfort.

Caregivers highlight palatability and convenience of Suprax suspension (100 mg/5 mL) for children, which supports adherence.

Forum & Community Pharmacy Trends

Pharmacists in large chains report frequent questions about dosing frequency, renal adjustments for seniors, and provincial coverage under ODB, BC PharmaCare, and RAMQ.

Common online searches include terms like suprax syrup for children and cefixime 400 mg price when families compare options.

Pharmacist counselling focuses on completing the course, watching for severe diarrhoea or allergic signs, and confirming proper weight‑based dosing in children.

Distribution & Pricing Landscape

National Pharmacy Chains

Major Canadian chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs routinely stock Suprax and generics, though availability by formulation varies by location.

Independent community pharmacies also carry cefixime products and can assist with substitution options when generics are preferred.

Online Pharmacy Availability & Provincial Restrictions

Province‑licensed online pharmacies offer prescription fulfilment and home delivery, and provincial drug plans determine coverage for eligible populations.

Treatment reimbursement differs by DIN and by provincial formularies; pharmacists can check ODB, BC PharmaCare, or RAMQ listings for specific patient eligibility.

Cross‑Border US Comparisons

Retail prices for Suprax and its generics in Canada are typically lower than many US list prices, but actual cost depends on generic availability and pharmacy markups.

Pharmacists generally advise against unsanctioned cross‑border purchases due to authenticity and regulatory differences between jurisdictions.

In our online pharmacy, suprax can be ordered with a valid prescription and is delivered discreetly to Canada in 5–14 days.

Alternative Options

Comparison Table Of DIN‑Approved Alternatives

Alternatives commonly available in Canada include cefpodoxime, cefuroxime, cefdinir, and amoxicillin/clavulanate (Augmentin).

Choice depends on organism susceptibility, indication, dosing convenience, adverse‑effect profile, and provincial formulary coverage.

Pros And Cons Checklist

• Cefpodoxime: similar spectrum; often twice‑daily dosing; pro: activity vs some resistant strains; con: cost and GI side effects.
• Cefuroxime: broader respiratory coverage; pro: established for sinusitis/bronchitis; con: twice‑daily dosing.
• Cefdinir: convenient dosing options; pro: patient convenience; con: lower activity for certain Enterobacterales.
• Amoxicillin/Clavulanate (Augmentin): effective for mixed infections; pro: broad coverage; con: higher diarrhoea risk.

Select alternatives using local antibiogram data and consider patient factors such as allergy history, renal function, and coverage under provincial plans.

Regulatory Status

Health Canada Approval Process

Cefixime products such as Suprax and generics are authorized in Canada after Health Canada review of quality, safety, and efficacy and are assigned DINs.

The products in Canada carry DIN 00868981 for the 400 mg tablet and DIN 00868965 for the 100 mg/5 mL suspension and remain prescription‑only.

Manufacturers and healthcare professionals must report adverse events to Health Canada and follow public safety communications for recalls or label changes.

DIN And Bilingual Labelling Rules

Packaging and patient leaflets must comply with bilingual labelling requirements (English/French) and include the DIN for provincial adjudication and reimbursement.

Provincial drug plans use DINs for listing decisions and reimbursement, so accurate DIN use on prescriptions supports patient coverage where applicable.

Consolidated FAQ

Q: Is Suprax available without a prescription in Canada?

A: No; Suprax is prescription‑only across Canada and requires a valid prescription for dispensing using DIN 00868981 or DIN 00868965.

Q: Can children take Suprax suspension and what is the dose?

A: Yes; the suspension (100 mg/5 mL) is for paediatrics older than six months, typically dosed at 8 mg/kg once daily or 4 mg/kg every 12 hours per the monograph.

Q: What if I miss a dose?

A: Take the missed dose as soon as you remember unless the next dose is near; do not double the dose.

Q: Does provincial coverage apply?

A: Coverage varies by province and by indication; pharmacists can help check ODB, BC PharmaCare, or RAMQ formularies for eligibility.

Q: Is it safe in pregnancy?

A: Cefixime is generally category B evidence and may be used if clearly indicated after discussion with the prescriber.

Visual Guide

Design three infographic panels for patient education: dosage, provincial coverage, and purchase channels.

Panel 1 (Dosage): show adult dosing — 400 mg once daily or 200 mg q12h — and pediatric weight‑based dosing 8 mg/kg once daily or 4 mg/kg q12h.

Panel 2 (Provincial Coverage): a map summarising ODB, BC PharmaCare, and RAMQ coverage flags using DIN references 00868981 and 00868965.

Panel 3 (Purchase Channels): flowchart from prescription to community pharmacy (Shoppers, Rexall, Jean Coutu, London Drugs) or licensed online pharmacy, pharmacist counselling, and provincial reimbursement check.

Accessibility notes: include bilingual labels, clear icons for renal‑adjust dose, allergy contraindication, and C. difficile warning, and provide printable A4 and mobile formats.

Storage & Transport

Canadian Household Guidelines

Store tablets and capsules at room temperature between 15 and 30°C and protect them from moisture; avoid bathroom storage where humidity fluctuates.

Keep medication in original packaging with the prescription label to aid identification and allow pharmacists to verify DINs if needed.

Cold‑Chain Storage Where Applicable

Unreconstituted oral suspension can be kept at room temperature until prepared; once reconstituted refrigerate and use within 14 days and discard any leftover after that period.

Avoid freezing suspensions and protect tablets from extreme heat during travel; for inter‑provincial travel, carry medication in original packaging with your prescription and health card.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Initiate cefixime only with an appropriate indication and, where possible, culture guidance to support targeted therapy.

Pharmacists will confirm allergy history, review renal function, advise a 50% dose reduction if CrCl <60 mL/min, and explain the importance of completing the course.

Advise patients to stop the medicine and seek urgent care for severe allergic reactions or extensive skin rash.

Provincial Health Authority Guidance

Ontario, BC, and Quebec emphasise antimicrobial stewardship — use the narrowest effective agent and avoid treating viral illnesses with antibiotics.

Pharmacists are encouraged to counsel on adherence, adverse‑event detection, and to support provincial formulary navigation for cost‑effective care.

Concluding Notes

Cefixime (Suprax) remains a useful oral third‑generation cephalosporin when used with stewardship principles and local susceptibility data.

Monitor elderly patients for renal function and diarrhoeal complications and use culture results or antibiogram data to guide therapy for suspected resistant pathogens such as gonorrhea.

Report serious adverse events to Health Canada and consult your pharmacist or prescriber for dosing adjustments and provincial coverage questions.

Delivery Across Canada (English)